Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples